Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | WDR91 | A4D1P6 | 2/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774412 | 0.89 | L3MBTL1 (0.66) | L3MBTL1HRH3WDR91ACACBRAB9A | |
| SCHEMBL1254047 | 0.87 | L3MBTL1 (0.69) | L3MBTL1HRH3WDR91ACACBRAB9A | |
| SCHEMBL11200681 | 0.86 | L3MBTL1 (0.76) | L3MBTL1HRH3WDR91ACACBTSHR | |
| SCHEMBL20702426 | 0.86 | L3MBTL1 (0.58) | L3MBTL1HRH3WDR91ACACBRAB9A | |
| SCHEMBL12639945 | 0.83 | L3MBTL1 (0.62) | L3MBTL1HRH3WDR91ACACBRAB9A | |
| SCHEMBL24920313 | 0.82 | WDR91 (0.57) | L3MBTL1HRH3WDR91ACACBRAB9A | |
| SCHEMBL22042582 | 0.82 | RAB9A (0.57) | L3MBTL1HRH3WDR91ACACBRAB9A | |
| SCHEMBL24754398 | 0.82 | L3MBTL1 (0.54) | L3MBTL1HRH3WDR91ACACBRAB9A | |
| SCHEMBL13853398 | 0.81 | L3MBTL1 (0.65) | L3MBTL1HRH3WDR91ACACBTSHR | |
| SCHEMBL9293223 | 0.81 | L3MBTL1 (0.65) | L3MBTL1HRH3WDR91ACACBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-8263595-B2 | Triazolopyridine compounds and their use as ask inhibitors | MERCK SERONO SA (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MAP3K5, MAPKAPK5, MAP3K9 | L3MBTL1 4658/4885HRH3 2386/4885WDR91 196/4885 |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MAP3K5, MAPKAPK5, MAP3K9 | L3MBTL1 4658/4885HRH3 2386/4885WDR91 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.